U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339384) titled 'Signatera Assessment in Early-Stage Endometrial Cancer' on Dec. 30, 2025.
Brief Summary: The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is:
* To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observ...